Press release
Antibacterial Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024
Request a sample pdf Copy of report @ https://www.coherentmarketinsights.com/insight/request-sample/177
Invention of Penicillin was a major breakthrough for treating bacterial infections. This stimulated research for more antibacterial drugs to treat different bacteria such as Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus (MRSA) and Enterococcus species. However, price control and decreasing financial incentives discouraged pharmaceutical companies to conduct further research in this field. This has limited treatment options for bacterial infections, while discovery of new strains of infectious bacteria is on rise. Below is the timeline of antibacterial drug discovery:
Antibacterial Drugs Market
The timeline highlights the large void in introduction of new antibacterial drugs during period 1960–2000. Streptomycin, sulfonamide, macrolide, nalidixic acid, aminoglycoside, tetracycline, and linezolid are among the bacterial resistant drugs.
Prospective drug candidates in research to improve the future outlook of the global antibacterial drugs market
The global antibacterial drugs market potential is estimated based on the current antibacterial drug classes, including those mentioned above and those in clinical trials. As of March 2016, there are around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S.
Moreover, FDA is encouraging development of new antibacterial drugs by laying out guidelines for the industry on the types of clinical studies to be conducted on antibacterial drug evaluation. This factor coupled with various incentives for research companies would create a positive outlook for the global antibacterial drugs resistance market in the near future.
Also, in March 2017, the WHO released a list of pathogens, classified based on the criticality/urgency, for which newer antibacterial drugs are required. The different environmental forces working towards development of newer antibacterial drugs would be a major continuing factor for the global antibacterial drugs market growth.
Alarming rise in drug resistant strains of bacteria driving awareness initiatives and programs by global healthcare organizations to back companies in the antibacterial drugs market
According to the Centers for Drug Disease Prevention and Control (CDC), every year at least 2 million people in the U.S. acquire bacterial infections that are resistant to drugs. Antibacterial resistance results in 23,000 deaths every year in the U.S. Moreover, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data of November 2016, antibiotic resistance is higher in southern and south-eastern Europe than in northern Europe.
Multiple drug resistance, as in case of tuberculosis, has further aggravated the treatment for specific conditions. According to the World health Organization (WHO), India has the highest burden of TB worldwide. Furthermore, the MDR-TB cases resistant to second-line drugs was 16% among already treated cases reported in 2015. Globally, an estimated 480,000 people developed MDR-TB in 2015 (WHO). The Government of India has drafted a national Strategic Plan 2017-2025 for eradicating TB in India. This would further propel the antibacterial drugs market in India.
Ask for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/177
The WHO has carved a ‘Global Action Plan on Antimicrobial Resistance’ in 2015 to fight against growing antibacterial resistance. CDC is also working in close collaboration with healthcare providers, pharmaceuticals companies, farmers, agriculture and environmental specialists, and representatives from Federal agencies to monitor, and control the prescription and use of antibacterial drugs. Such initiatives are expected to hold drugs for the future generation until the new drug launch and thus drive the antibacterial drugs market.
Some of the major players in the global antibacterial drugs market are Pfizer, Inc., Johnson & Johnson, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Evotec Pharmaceuticals, Allecra Therapeutics, Kyorin Pharmaceutical, and Allergan plc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights
E-mail : sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibacterial Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 here
News-ID: 790627 • Views: 255
More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…

Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic…

Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to…

Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…